PubMed Health⌕ Search

Biomedical subjects

Ying-Hua Chen

Publications and source records attributed to Ying-Hua Chen.

At least 19 recordsLinked to original sources

The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation.

The HIV-1 gp41 (glycoprotein 41) core plays a critical role in fusion between the viral and target cell membranes. We previously identified a gp41 core-binding motif, HXXNPF, by screening the phage display peptide libraries. In the present study, we elucidated the mechanism of action of HXXNPF motif-containing molecules of different sizes, including the phage clone L7.8 (a selected positive phage clone), L7.8-g3p* (a 10-kDa fragment of the gene 3 protein) and JCH-4 (a peptide containing 13 residues of L7.8-g3p*), regarding their respective binding abilities to the six-helix bundle and inhibition on syncytium formation at different temperatures. We found that all of the HXXNPF motif-containing molecules could bind to the gp41 core, and that their binding sites may be located in the N-helix domain. L7.8-g3p* and JCH-4 effectively inhibited HIV-1 Env (envelope glycoprotein)-mediated syncytium formation at 37 degrees C, while the phage clone L7.8 showed no inhibition under the same conditions. However, at suboptimal temperature (31.5 degrees C), all of these HXXNPF motif-containing molecules were capable of inhibiting syncytium formation. These results suggest that these HXXNPF motif-containing molecules mainly bind to the gp41 core and stop the fusion process mediated by the fusion-active core, resulting in inhibition of HIV-1 fusion and entry. The HXXNPF motif-containing molecules may be used as probes for studying the role of the HIV-1 gp41 core in the late stage of the membrane-fusion process.

3T3 Cells↗

Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1.

The human immunodeficiency virus, type 1 (HIV-1) gp41 core plays an important role in fusion between viral and target cell membranes. A single chain polypeptide, N36(L8)C34, which forms a six-helix bundle in physiological solution, can be used as a model of gp41 core. Here we identified from a 12-mer phage peptide library a positive phage clone displaying a peptide sequence with high binding activity to the HIV-1 gp41 core. The peptide sequence contains a putative gp41-binding motif, PhiXXXXPhiXPhi (X is any amino acid residue, and Phi is any one of the aromatic amino acid residues Trp, Phe, or Tyr). This motif also exists in the scaffolding domain of caveolin-1 (Cav-1), a known gp41-binding protein. Cav-1-(61-101) and Cav-1-(82-101), two recombinant fusion proteins containing the Cav-1 scaffolding domain, bound significantly to the gp41 expressed in mammalian cells and interacted with the polypeptide N36(L8)C34. These results suggest that the scaffolding domain of Cav-1 may bind to the gp41 core via the motif. This interaction may be essential for formation of fusion pore or endocytosis of HIV-1 and affect the pathogenesis of HIV-1 infection. Further characterization of the gp41 core-binding motifs may shed light on the alternative mechanism by which HIV-1 enters into the target cell.

Amino Acid Motifs↗

Surface simulation synthesis: a new strategy to spy alpha-helix structure.

In key proteins, there are always some alpha-helix structures, which play important role in the structure and functions. Many epitopes lie on the surface of alpha-helix. These epitopes are not easy to be recruited into the vaccine development, because they are conformation dependent epitopes. Can such epitopes on alpha-helix be mimicked synthetically? Our findings undoubtedly validate the feasibility of surface simulation synthesis with short linear peptide to mimic the antigenic side of alpha-helix structure.

Amino Acid Sequence↗

Marker vaccine strategies and candidate CSFV marker vaccines.

Classical swine fever (CSF) is an economically important highly contagious disease of swine worldwide. Classical swine fever virus (CSFV) is its etiological agent, and the only natural hosts are domestic pigs and wild boars. Although field CSFV strains vary in the virulence, they all result in serious losses in pig industry. Highly virulent field strains generally cause acute disease and high mortality; moderately virulent field strains raise subacute or chronic infections; postnatal infection by low virulent field strains produces subclinical infection and mortality in the new-born piglets. CSFV can cross the placental barrier, and this transplacental transmission usually results in mortality of fetuses and birth of congenitally infected pigs with a late-onset disease and death. Two main strategies to control CSF epidemic are systematic prophylactic vaccination with live attenuated vaccines (such as C-strain) and non-vaccination stamping-out policy. But neither of them is satisfying enough. Marker vaccine and companion serological diagnostic test is thought to be a promising strategy for future control and eradication of CSF. During the past 15 years, various candidate marker vaccines were constructed and evaluated in the animal experiments, including recombinant chimeric vaccines, recombinant deletion vaccines, DNA vaccines, subunit vaccines and peptide vaccines. Among them, two subunit vaccines entered the large scale marker vaccine trial of EU in 1999. Although they failed to fulfil all the demands of the Scientific Veterinary Committee, they successfully induced solid immunity against CSFV in the vaccinated pigs. It can be expected that new potent marker vaccines might be commercially available and used in systematic prophylactic vaccination campaign or emergency vaccination in the next 15 years. Here, we summarized current strategies and candidate CSFV marker vaccines. These strategies and methods are also helpful for the development of new-generation vaccines against other diseases.

Animals↗

Identification of the HIV-1 gp41 core-binding motif--HXXNPF.

The HIV-1 gp41 core, a six-helix bundle formed between the N- and C-terminal heptad repeats, plays a critical role in fusion between the viral and target cell membranes. Using N36(L8)C34 as a model of the gp41 core to screen phage display peptide libraries, we identified a common motif, HXXNPF (X is any of the 20 natural amino acid residues). A selected positive phage clone L7.8 specifically bound to N36(L8)C34 and this binding could be blocked by a gp41 core-specific monoclonal antibody (NC-1). JCH-4, a peptide containing HXXNPF motif, effectively inhibited HIV-1 envelope glycoprotein-mediated syncytium-formation. The epitope of JCH-4 was proven to be linear and might locate in the NHR regions of the gp41 core. These data suggest that HXXNPF motif may be a gp41 core-binding sequence and HXXNPF motif-containing molecules can be used as probes for studying the role of the HIV-1 gp41 core in membrane fusion process.

3T3 Cells↗

Neutralizing epitopes in the membrane-proximal region of HIV-1 gp41: genetic variability and co-variation.

Recent investigations on the passive immunization have proved that neutralizing antibodies directed to the membrane-proximal region of HIV-1 gp41 are potent anti-viral components, so this region is thought to be an attractive target for AIDS vaccine. Three key neutralizing epitopes, ELDKWA (aa662-667), NWFDIT (aa671-676) and ERDRDR (aa739-744) have been mapped in this region. In this study, their genetic variability and co-variation was evaluated. There exists marked shift in the predominant sequence patterns on these three neutralizing epitopes over time. Compared with subtype B, non-B clades exhibit significant genetic variability and co-variation on these three epitopes. Among HIV-1 strains isolated in recent 5 years, about one third displays epitope variants simultaneously on three epitopes. The newly isolated strains with co-variations on several neutralizing epitopes ought to be of strict surveillance in clinical treatment, and those frequent epitope variants should also be considered in vaccine design.

AIDS Vaccines↗

Spying the neutralizing epitopes on E2 N-terminal by candidate epitope-vaccines against classical swine fever virus.

Our previous study proved that the N-terminal (aa693-711) of glycoprotein E2 contained sequential neutralizing epitopes. In this study, four candidate epitope-vaccines (EVs) were separately prepared and evaluated. Among them, epitope-vaccine EV-BC1a (BC1a: aa693-699) induced high level of epitope-specific neutralizing antibodies and exhibited similar protective capability with that induced by Chinese vaccine strain (C-strain). These results confirmed CKEDYRY (aa693-699) as a principal sequential neutralizing epitope on E2 N-terminal. Moreover, these findings also indicate that epitope-vaccine is a potent candidate strategy for marker vaccine against classical swine fever virus (CSFV).

Amino Acid Sequence↗

Candidate peptide-vaccines induced immunity against CSFV and identified sequential neutralizing determinants in antigenic domain A of glycoprotein E2.

Antigenic domain A is a highly conserved unit on envelope protein E2 of classical swine fever virus (CSFV). It was found that mutant E2 containing only unit A, with the unit BC deleted, provided immunized pigs with complete protection against the lethal challenge. In this study, six overlapping peptides (A1-A6) covering this unit were synthesized and conjugated to bovine serum albumin (BSA). Two candidate multi-peptide-vaccines (MPVs) using aluminum adjuvant successfully induced potent immunity against CSFV in pigs. Although both candidate MPVs failed to provide complete protection, they showed better protective activity than that induced by C-strain. Subsequently, neutralizing epitopes in unit A were identified using a panel of peptide-vaccines (PVs). Six candidate peptide-vaccines (PV-An, n=1-6) were separately given to six groups of pigs. Among these candidates, PV-A2 and PV-A6 exhibited the most potent protective activity, while the other four showed weaker or almost no effects. Moreover, the polyclonal antibodies induced by PV-A2 and PV-A6 were capable of neutralizing C-strain virus at the dilution 1:16 in vitro. Thus, two principal sequential neutralizing determinants covered by peptide A2 (aa792-814) and A6 (aa844-865) were demonstrated to exist in the antigenic domain A, and can be recruited in developing new effective "marker vaccine" against CSFV.

Adjuvants, Immunologic↗

The antigenic tip GPGRAFY of the V3 loop on HIV-1 gp120: genetic variability and subtypes.

V3 loop on HIV-1 gp120 is tightly correlated with syncytium formation, coreceptor usage, virus infectivity and antibody neutralization. The antigenic tip GPGRAFY with its flanking sequence has a conserved secondary structure, and is the target of neutralizing antibodies. We analyzed its genetic variability in 30096 M-group isolates and 269 O-group isolates. Subtype-related restricted mutations were observed, which could help to identify subtypes.

Amino Acid Motifs↗

Genetic variability of principal neutralizing determinants on HIV-1 gp41 and its correlation with subtypes.

Several neutralizing determinants have been identified on HIV-1 envelope glycoprotein gp41: LGIWGCSGKLIC (HXB2: aa593-604), ELDKWA (aa662-667), NWFDIT (aa671-676), and ERDRDR (aa739-744). Restricted mutations were observed on these epitopes. In this study, the genetic variability of these neutralizing determinants in 3799 isolates from different M-group subtypes (A, B, C, D, F, G, H, CRF01_AE and CRF02_AG) and O group was analyzed. Many variants were found to be closely correlated with certain subtypes. These subtype-related variants could be recruited into the subtype identification and subtype-specific vaccine development.

Amino Acid Motifs↗

The neutralizing epitope ELDKWA on HIV-1 gp41: genetic variability and antigenicity.

Viral evasion through mutations of neutralizing epitopes is a major challenge to AIDS vaccine development and clinical therapy. In this study, we analyzed the genetic variability of principal neutralizing epitope ELDKWA among 5393 HIV isolates in the HIV sequence database (). It has been found that six out of seven frequent variants were able to cause the invalidation of famous neutralizing MAb 2F5. Moreover, escape mutations K665S and K665E, often observed in C-subtype and O-group strains, respectively, were reported more frequently in recent years. Furthermore, we studied the antigenicity of these variants. Polyclonal antibodies induced by a candidate multi-epitope-vaccine were able to react with the recombinant gp41, respectively, carrying these variants, indicating that "epitope cocktail" strategy is necessary and helpful in vaccine design.

Amino Acid Motifs↗

Candidate peptide-vaccine induced potent protection against CSFV and identified a principal sequential neutralizing determinant on E2.

Previously, two candidate multi-peptide-vaccines (MPVs) consisted of five overlapping synthetic peptides covering the antigenic domain B/C (aa693-777) on envelope protein E2 were prepared in our lab. And they successfully induced peptide-specific neutralizing antibodies and provided pigs with complete protection from the lethal challenge of virulent classical swine fever virus (CSFV) strain Shimen. In this study, these five peptides were conjugated to bovine serum albumin (BSA), with which five groups of pigs (n=10) were inoculated, respectively. Among these candidate peptide-vaccines (PVs), PV-BC1 (BC1: aa693-716) exhibited the most potent protective activity, PV-BC3, PV-BC4 and PV-BC5 (BC3: aa723-745; BC4: aa741-760; BC5: aa757-777) had weaker effects, while no effect of PV-BC2 (BC2: aa712-727) had been detected. Moreover, the polyclonal antibodies induced by PV-BC1 and PV-BC4 were capable of neutralizing C-strain virus in vitro. Thus, a principal sequential neutralizing determinant (aa693-716) and a minor sequential neutralizing determinant (aa741-760) were proved to lie in the antigenic domain B/C, which can be recruited into developing more effective "marker vaccine" by epitope-vaccine strategy. Our study also indicates that scanning with a panel of sequential peptide-immunogens is an effective method to locate sequential neutralizing epitopes.

Animals↗

Candidate multi-peptide-vaccine against classical swine fever virus induced potent immunity with serological marker.

Our previous study proposed a protective multi-peptide-vaccine (MPV) with Freund's adjuvant against classical swine fever virus (CSFV). In this study, another candidate MPV, using aluminum adjuvant, was further examined. All immunized pigs kept healthy during the experimental period, while the control group rapidly showed clinical symptoms and died. Moreover, anti-sera from MPV-immunized pigs could interact with peptides involved in the MPV, in contrast to anti-sera from non-immunized or infected ones. This property permits MPV-immunized pigs to be easily differentiated from infected ones with simple serological method. Therefore, this new MPV is suitable to act as a candidate marker vaccine against CSFV.

Adjuvants, Immunologic↗

Predefined spacers between epitopes on a recombinant epitope-peptide impacted epitope-specific antibody response.

We have developed a widely applicable method to construct epitope-peptide gene for epitope-vaccine strategy recently. In this study, we wanted to know whether the predefined spacers between epitopes on a recombinant epitope-peptide impacted the production of epitope-specific antibodies. The neutralizing epitope ELDKWA on the C-domain of HIV-1 gp41 was defined by the monoclonal antibody (mAb) 2F5 with broad neutralizing activity. We constructed three recombinant ELDKWA-epitope-peptides with different spacers between epitopes. The recombinant epitope-peptide GST-K8, GST-S8 and GST-R8 were bearing eight copies of ELDKWA-epitope with amino acid spacer GS, GSGGGGS and RS, respectively. GST-K8 and GST-S8 could induce high titer of ELDKWA-epitope-specific antibodies, much better than GST-R8. Besides, both antibodies could recognize the recombinant soluble gp41 and the transfected CHO-WT cells that stably express HIV-1 envelope glycoprotein on the cell surfaces. These experimental results indicated that the spacer GSGGGGS and GS were feasible in constructing a recombinant epitope-vaccine.

Animals↗

High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins.

Although early studies have shown a close correlation between epitope density and epitope-specific humoral immune responses, few attempts have been made to quantitatively compare the antigenic and immunogenic differences between protein molecules bearing low or high degrees of epitope density, nor have studies quantitatively investigated the mechanism of B cell discrimination of monomeric antigens. In this study, we prepared glutathione S-transferase (GST) fusion proteins bearing various copies of the M2e epitope from the influenza virus M2 protein [GST-(M2e)8, GST-(M2e)4 and GST-(M2e)1], which were used to detect and compare the real-time kinetic binding with M2e-specific mAb by surface plasma resonance. Our data show clearly that fusion proteins bearing higher M2e epitope density resulted in higher average avidity for M2e-specific mAb. Furthermore, it was observed that fusion proteins bearing high M2e epitope density could induce polyclonal antibodies (pAb) with enhanced an average affinity constant (KA) for M2e epitope peptide compared to fusion proteins bearing low epitope density. The average KA of pAb induced by GST-(M2e)8 (3.08 x 10(8) M(-1) or 9.96 x 10(8) M(-1)) was up to two orders of magnitude greater than the average KA of pAb induced by GST-(M2e)1 (2.00 x 10(6) M(-1) or 3.43 x 10(6) M(-1)). Thus, the data presented here demonstrate that high epitope density in a single protein molecule significantly enhances antigenicity and immunogenicity. These findings enrich our knowledge of how epitope density might relate to the recognition, activation and antibody production processes of epitope-specific immature B cells.

Animals↗

Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies.

ELDKWA on HIV-1 gp41 is a conserved epitope recognized by one broadly neutralizing monoclonal antibody 2F5, which is a promising candidate target for vaccine design. Here we report two ELDKWA-specific monoclonal antibodies (mAbs), 18F11 and 7E10, that were screened from the splenocytes of mice immunized by recombinant GST-(ELDKWA)4 protein. In further evaluation, these mAbs exhibited appreciable neutralizing activities against HIV-1 primary isolate 92US675 (clade B) with IC50 (50% inhibition concentration) of 6.84 +/- 0.36 microg/ml and 10.66 +/- 1.69 microg/ml, respectively. Unexpectedly, neither of these two murine mAbs could neutralize laboratory-adapted strain HIV-1 IIIB (clade B). As a control, human mAb 2F5 neutralized both primary and laboratory-adapted strains. These data strongly suggest that ELDKWA-specific antibodies induced by different antigenic formats show different neutralizing activities against HIV-1, which implies another complication in the development of effective vaccines.

Amino Acid Sequence↗

The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection.

Based on our previous study that the monoclonal antibody (mAb) 8C6 recognizing the extracellular domain of influenza A virus M2 protein (M2e) could passively induce protective immunity in mice, epitope mapping was performed in this study. A series of eight mutated M2e were constructed and expressed. It was found in immunoblotting assay that 8C6 could not bind to two of the mutated M2e proteins, which suggested the VETPIR epitope (aa7-12) in M2e for mAb 8C6. More important, EVETPIRN-peptide (aa6-13) conjugated immunogen induced high M2e specific antibody titer (1:25,600) in mice after booster immunization, and provided mice significantly 40% higher survival rate compared with the control group in challenge assay (p=0.0215), which suggested the EVETPIRN-epitope was immunogenic and actively conferred immune protection to some extent. In addition, sequence comparison suggested the EVETPIRN sequence (aa6-13) was highly conserved in all human influenza A strains. All these data suggested the EVETPIRN sequence in M2e could be one new target for influenza vaccine design.

Amino Acid Sequence↗